髋关节假体周围感染再次二期翻修术:平均随访10年的多中心研究
该多中心回顾性研究纳入1991年至2022年因慢性髋关节假体周围感染接受再次二期翻修的患者,52例中36例完成二期植入,平均随访10.7年。按2019年肌肉骨骼感染学会Tier 1标准,治疗成功21/36例(58.3%),5年全因假体生存率66.2%,无假体周围感染生存率76.4%,未发现失败预测因素。
要点
- 36例完成再次二期翻修者中治疗成功21例(58.3%),再次感染11例。
- 5年全因假体生存率66.2%,无假体周围感染生存率76.4%,平均随访10.7年。
- 体质指数、美国麻醉医师协会分级、McPherson宿主分级均未预测失败。
核心结论
- 髋关节假体周围感染再次二期翻修成功率低,即使经过仔细筛选的患者也是如此,作者认为应进行现实的患者沟通、多学科诊疗并考虑替代策略。
研究设计与样本
- 回顾性分析两家三级中心前瞻性维护的数据库,纳入1991年至2022年间因慢性髋关节假体周围感染接受再次二期翻修的患者。
- 共52例符合纳入标准,其中16例未进行二期植入,36例完成再次二期翻修,平均随访10.7年(范围0.3至33.4年)。
- 治疗成功采用2019年肌肉骨骼感染学会Tier 1标准定义,采用Kaplan-Meier生存分析和Cox回归评估结局与再感染预测因素。
主要发现
- 按肌肉骨骼感染学会Tier 1标准,36例中21例(58.3%)治疗成功。
- 5年全因假体生存率为66.2%,无假体周围感染生存率为76.4%。
- 末次随访时11例出现复发性假体周围感染,15例需要进一步手术或长期抑制性抗生素治疗。
- 体质指数、美国麻醉医师协会分级、McPherson宿主分级等变量均不能预测失败。
- 培养阳性病例中47.2%观察到致病菌变化。
关键数值与推荐
- 治疗成功定义采用2019年肌肉骨骼感染学会Tier 1标准。
- 治疗成功21/36例(58.3%);5年全因假体生存率66.2%,无假体周围感染生存率76.4%。
- 培养阳性病例中致病菌变化者占47.2%。
临床怎么用
- 作者认为再次二期翻修治疗髋关节假体周围感染成功率低,强调现实的患者沟通、多学科诊疗并考虑替代策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Repeat two-stage revision remains a salvage option for managing recurrent periprosthetic joint infection (PJI) of the hip after a failed initial revision. However, the evidence base for this approach is limited. This study aimed to evaluate treatment outcomes and identify risk factors for failure following repeat two-stage revision arthroplasty for hip PJI. METHODS: We conducted a retrospective review of prospectively maintained databases from two tertiary centers to identify patients who underwent repeat two-stage revision for chronic hip PJI between 1991 and 2022. Treatment success was defined using the 2019 Musculoskeletal Infection Society Tier 1 criteria. Kaplan-Meier survivorship analysis and Cox regressions were used to assess outcomes and potential predictors of reinfection. There were 52 patients who met the inclusion criteria. There were 16 patients who did not proceed to second-stage implantation, leaving 36 cases who completed repeat two-stage exchange. Mean follow-up of 10.7 years (range, 0.3 to 33.4). RESULTS: Using Musculoskeletal Infection Society Tier-1 criteria, treatment success was achieved in 21 of 36 patients (58.3%). All-cause implant survival was 66.2% at five years, while survival free from PJI was 76.4%. At final follow-up, recurrent PJI occurred in 11 cases, with further surgery or long-term suppressive antibiotics required in 15 patients. There were no variables, including body mass index, American Society of Anesthesiologists, or McPherson host grade, predictive of failure. A change in causative organism was observed in 47.2% of culture-positive cases. CONCLUSIONS: Repeat two-stage revision for hip PJI is associated with low success rates, even in carefully selected patients. These findings highlight the complexity of managing recurrent infection and underscore the need for realistic counseling, multidisciplinary care, and consideration of alternative strategies.
引用
- Kennedy IW, Howard LC, Somerville L, et al. Repeat Two-Stage Revision Arthroplasty for Periprosthetic Joint Infection of the Hip: A Multicenter Study With a Mean 10-Year Follow-Up. J Arthroplasty. 2026. PMID: 41534620. doi:10.1016/j.arth.2026.01.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。